一个基于语音的预后模型,用于ALS中异性关节炎的进展
Gabriela Stegmann1,2, Sherman Charles2,3, Julie Liss1,2
1Arizona State University, Phoenix, AZ, United States.
概括
这项研究使用语音录音的发音精度预测了肌缩侧面硬化症 (ALS) 语音障碍. 该模型准确地预测了ALS患者未来的语音下降.
科学领域:
- 神经学 神经学
- 语音语言病理学 语音语言病理学
- 生物医学工程 生物医学工程
背景情况:
- 肌缩侧面硬化症 (ALS) 逐渐影响言语,影响患者的沟通和生活质量.
- 准确预测语音障碍对于及时干预和ALS患者管理至关重要.
- 现有的评估ALS语音衰退的方法可能缺乏精确,个性化的预测的细节性.
研究的目的:
- 开发和验证一种预后模型,用于预测ALS患者未来的语言障碍.
- 确定从语音录音中测量关节精度的临床实用性,用于ALS进展监测.
- 为了将语音的声学测量与已建立的临床尺度 (如ALSFRS-R语音分数) 相关联起来.
主要方法:
- 利用两项ALS研究中的纵向语音录音和ALSFRS-R语音子谱.
- 开发了一种算法,通过分析语音样本中的语音声学来量化发音精度.
- 对表达精度测量与感知评级进行了验证,并使用它来构建未来语音能力的预测模型.
主要成果:
- 在关节精度方面建立了强大的分析和临床有效性 (r = .9与感知等级).
- 通过45-90天的校准期,成功预测了30-90天前的关节精度.
- 实现了较低的平均绝对误差:4%的表达精度和14%的ALSFRS-R语音分数.
结论:
- 一个特定对象的预后模型准确地预测了ALS患者未来的关节精度.
- 该模型有效地预测ALSFRS-R语音分数,为临床评估提供了有价值的工具.
- 这种方法使得精确的,数据驱动的预测能够在患有ALS的个体中预测语音衰退.
相关概念视频
Alzheimer's Disease: Overview
532
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
532
Parkinson's Disease: Overview
611
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
611
Alzheimer's Disease: Treatment
223
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
223


